{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T18:07:05Z","timestamp":1792951625368,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Natural Science Foundation joint fund project of Shandong Province","award":["ZR2022LSW030"],"award-info":[{"award-number":["ZR2022LSW030"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-026-02108-8","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T13:35:51Z","timestamp":1776519351000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk prediction model of survival in patients with low-grade serous ovarian cancer: a multicenter Cohort study"],"prefix":"10.1186","volume":"19","author":[{"given":"Ying","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongshao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuecheng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingbao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanming","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baochen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"issue":"11","key":"2108_CR1","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s11912-022-01315-y","volume":"24","author":"RN Grisham","year":"2022","unstructured":"Grisham RN, Chui MH. Advancements in low-grade serous carcinoma of the ovary and peritoneum. Curr Oncol Rep. 2022;24(11):1549\u201355. https:\/\/doi.org\/10.1007\/s11912-022-01315-y.","journal-title":"Curr Oncol Rep"},{"key":"2108_CR2","doi-asserted-by":"publisher","first-page":"102458","DOI":"10.1016\/j.ctrv.2022.102458","volume":"110","author":"L Musacchio","year":"2022","unstructured":"Musacchio L, Valsecchi AA, Salutari V, et al. MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2022;110:102458. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102458.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"2108_CR3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.ygyno.2019.12.033","volume":"156","author":"B Slomovitz","year":"2020","unstructured":"Slomovitz B, Gourley C, Carey MS, et al. Low-grade serous ovarian cancer: State of the science. Gynecol Oncol. 2020;156(3):715\u201325. https:\/\/doi.org\/10.1016\/j.ygyno.2019.12.033.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"2108_CR4","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1097\/PAS.0b013e31803199b0","volume":"31","author":"A Malpica","year":"2007","unstructured":"Malpica A, Deavers MT, Tornos C, et al. Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol. 2007;31(8):1168\u201374. https:\/\/doi.org\/10.1097\/PAS.0b013e31803199b0.","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"2108_CR5","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","volume":"35","author":"DM Gershenson","year":"2017","unstructured":"Gershenson DM, Bodurka DC, Coleman RL, et al. Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J Clin Oncol. 2017;35(10):1103\u201311. https:\/\/doi.org\/10.1200\/JCO.2016.71.0632.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2108_CR6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.ygyno.2020.06.498","volume":"158","author":"LP Cobb","year":"2020","unstructured":"Cobb LP, Sun CC, Iyer R, et al. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: further evidence of relative chemoresistance. Gynecol Oncol. 2020;158(3):653\u20138. https:\/\/doi.org\/10.1016\/j.ygyno.2020.06.498.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"2108_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/cac2.12067","volume":"40","author":"J Wu","year":"2020","unstructured":"Wu J, Zhang H, Li L, et al. A nomogram for predicting overall survival in patients with low-grade endometrial stromal sarcoma: a population-based analysis. Cancer Commun. 2020;40(7):301\u201312. https:\/\/doi.org\/10.1002\/cac2.12067.","journal-title":"Cancer Commun"},{"issue":"5","key":"2108_CR8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/curroncol32050263","volume":"32","author":"J Zhang","year":"2025","unstructured":"Zhang J, Wang M, Wu Y. Risk factors for recurrence in serous borderline ovarian tumors and early-stage low-grade serous ovarian carcinoma. Curr Oncol. 2025;32(5):263. https:\/\/doi.org\/10.3390\/curroncol32050263.","journal-title":"Curr Oncol"},{"issue":"1","key":"2108_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3892\/mco.2024.2745","volume":"21","author":"H Alhusaini","year":"2024","unstructured":"Alhusaini H, Badran A, Al Juhani A, et al. Outcome and prognostic factors of low\u2013grade serous ovarian cancer: an observational retrospective study. Mol Clin Oncol. 2024;21(1):47. https:\/\/doi.org\/10.3892\/mco.2024.2745.","journal-title":"Mol Clin Oncol"},{"issue":"12","key":"2108_CR10","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1136\/ijgc-2023-004745","volume":"33","author":"D Nasioudis","year":"2023","unstructured":"Nasioudis D, Wang X, Dhillon G, et al. Impact of adjuvant chemotherapy on the overall survival of patients with advanced-stage low-grade serous ovarian carcinoma following primary cytoreductive surgery. Int J Gynecol Cancer. 2023;33(12):1906\u201312. https:\/\/doi.org\/10.1136\/ijgc-2023-004745.","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"2108_CR11","doi-asserted-by":"publisher","first-page":"e1209","DOI":"10.1097\/SLA.0000000000003803","volume":"274","author":"YY Wang","year":"2020","unstructured":"Wang YY, Xiang BD, Ma L, et al. Development and validation of a nomogram to preoperatively estimate post-hepatectomy liver dysfunction risk and long-term survival in patients with hepatocellular carcinoma. Ann Surg. 2020;274(6):e1209\u201317. https:\/\/doi.org\/10.1097\/SLA.0000000000003803.","journal-title":"Ann Surg"},{"issue":"1","key":"2108_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13048-022-00958-6","volume":"15","author":"L Yang","year":"2022","unstructured":"Yang L, Yu J, Zhang S, et al. A prognostic model of patients with ovarian mucinous adenocarcinoma: a population-based analysis. J Ovarian Res. 2022;15(1):26. https:\/\/doi.org\/10.1186\/s13048-022-00958-6.","journal-title":"J Ovarian Res"},{"issue":"1","key":"2108_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s12325-021-01955-9","volume":"39","author":"J Gao","year":"2021","unstructured":"Gao J, Wang S, Li F, et al. Nomograms for predicting overall survival and cancer-specific survival of young patients with epithelial ovarian cancer: analysis based on SEER program. Adv Ther. 2021;39(1):257\u201385. https:\/\/doi.org\/10.1007\/s12325-021-01955-9.","journal-title":"Adv Ther"},{"issue":"2","key":"2108_CR14","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.acra.2024.09.001","volume":"32","author":"X Huang","year":"2025","unstructured":"Huang X, Huang Y, Liu K, et al. Intratumoral and peritumoral radiomics for predicting the prognosis of high-grade serous ovarian cancer patients receiving platinum-based chemotherapy. Acad Radiol. 2025;32(2):877\u201387. https:\/\/doi.org\/10.1016\/j.acra.2024.09.001.","journal-title":"Acad Radiol"},{"issue":"4","key":"2108_CR15","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3390\/diagnostics13040748","volume":"13","author":"L Liu","year":"2023","unstructured":"Liu L, Wan H, Liu L, et al. Deep learning provides a new magnetic resonance imaging-based prognostic biomarker for recurrence prediction in high-grade serous ovarian cancer. Diagnostics (Basel). 2023;13(4):748. https:\/\/doi.org\/10.3390\/diagnostics13040748.","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"2108_CR16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13048-024-01482-5","volume":"17","author":"S Sarkar","year":"2024","unstructured":"Sarkar S, Saha SA, Swarnakar A, et al. The molecular prognostic score, a classifier for risk stratification of high-grade serous ovarian cancer. J Ovarian Res. 2024;17(1):159. https:\/\/doi.org\/10.1186\/s13048-024-01482-5.","journal-title":"J Ovarian Res"},{"issue":"4","key":"2108_CR17","doi-asserted-by":"publisher","first-page":"e3811","DOI":"10.1016\/j.ajog.2018.12.030","volume":"220","author":"K Matsuo","year":"2019","unstructured":"Matsuo K, Purushotham S, Jiang B, et al. Survival outcome prediction in cervical cancer: Cox models vs deep-learning model. Am J Obstet Gynecol. 2019;220(4):e3811\u201338114. https:\/\/doi.org\/10.1016\/j.ajog.2018.12.030.","journal-title":"Am J Obstet Gynecol"},{"key":"2108_CR18","doi-asserted-by":"publisher","first-page":"106851","DOI":"10.1016\/j.ijsu.2022.106851","volume":"105","author":"W Lee","year":"2022","unstructured":"Lee W, Park HJ, Lee HJ, et al. Preoperative data-based deep learning model for predicting postoperative survival in pancreatic cancer patients. Int J Surg. 2022;105:106851. https:\/\/doi.org\/10.1016\/j.ijsu.2022.106851.","journal-title":"Int J Surg"},{"issue":"5","key":"2108_CR19","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1097\/JS9.0000000000001222","volume":"110","author":"S Chen","year":"2024","unstructured":"Chen S, Gao F, Guo T, et al. Deep learning-based multi-model prediction for disease-free survival status of patients with clear cell renal cell carcinoma after surgery: a multicenter cohort study. Int J Surg. 2024;110(5):2970\u20137. https:\/\/doi.org\/10.1097\/JS9.0000000000001222.","journal-title":"Int J Surg"},{"key":"2108_CR20","doi-asserted-by":"publisher","first-page":"1069673","DOI":"10.3389\/fgene.2022.1069673","volume":"13","author":"M Wu","year":"2023","unstructured":"Wu M, Zhu C, Yang J, et al. Exploring prognostic indicators in the pathological images of ovarian cancer based on a deep survival network. Front Genet. 2023;13:1069673. https:\/\/doi.org\/10.3389\/fgene.2022.1069673.","journal-title":"Front Genet"},{"issue":"12","key":"2108_CR21","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.3390\/biomedicines12122881","volume":"12","author":"E Spirina Menand","year":"2024","unstructured":"Spirina Menand E, De Vries-Brilland M, Tessier L, et al. Learning to Train and to Explain a Deep Survival Model with Large-Scale Ovarian Cancer Transcriptomic Data. Biomedicines. 2024;12(12):2881. https:\/\/doi.org\/10.3390\/biomedicines12122881.","journal-title":"Biomedicines"},{"issue":"2","key":"2108_CR22","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ygyno.2016.11.019","volume":"144","author":"M Matz","year":"2017","unstructured":"Matz M, Coleman MP, Carreira H, et al. Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). Gynecol Oncol. 2017;144(2):396\u2013404. https:\/\/doi.org\/10.1016\/j.ygyno.2016.11.019.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"2108_CR23","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.3390\/cancers14081954","volume":"14","author":"C Wohlmuth","year":"2022","unstructured":"Wohlmuth C, Djedovic V, Kjaer SK et al. CA-125 levels are predictive of survival in low-grade serous ovarian cancer-a multicenter analysis. Cancers (Basel). 2022;14(8):1954. https:\/\/doi.org\/10.3390\/cancers14081954.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2108_CR24","doi-asserted-by":"publisher","first-page":"20012","DOI":"10.1038\/s41598-020-77075-1","volume":"10","author":"JH Kang","year":"2020","unstructured":"Kang JH, Lai YL, Cheng WF, et al. Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan. Sci Rep. 2020;10(1):20012. https:\/\/doi.org\/10.1038\/s41598-020-77075-1.","journal-title":"Sci Rep"},{"issue":"8","key":"2108_CR25","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1136\/ijgc-2022-004249","volume":"33","author":"AM Perrone","year":"2023","unstructured":"Perrone AM, Coada CA, Ravegnini G, et al. Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer. 2023;33(8):1270\u20138. https:\/\/doi.org\/10.1136\/ijgc-2022-004249.","journal-title":"Int J Gynecol Cancer"},{"issue":"21","key":"2108_CR26","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.7150\/jca.26220","volume":"9","author":"C Wang","year":"2018","unstructured":"Wang C, Yang C, Wang W, et al. A Prognostic Nomogram for Cervical Cancer after Surgery from SEER Database. J Cancer. 2018;9(21):3923\u20138. https:\/\/doi.org\/10.7150\/jca.26220.","journal-title":"J Cancer"},{"issue":"1","key":"2108_CR27","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/ERC-21-0191","volume":"29","author":"T Moujaber","year":"2022","unstructured":"Moujaber T, Balleine RL, Gao B, et al. New therapeutic opportunities for women with low-grade serous ovarian cancer. Endocr-relat Cancer. 2022;29(1):R1\u201316. https:\/\/doi.org\/10.1530\/ERC-21-0191.","journal-title":"Endocr-relat Cancer"},{"issue":"10","key":"2108_CR28","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1245\/s10434-020-08361-5","volume":"27","author":"V Simon","year":"2020","unstructured":"Simon V, Ngo C, Pujade-Lauraine E, et al. Should we abandon systematic pelvic and paraaortic lymphadenectomy in low-grade serous ovarian cancer?. Ann Surg Oncol. 2020;27(10):3882\u201390. https:\/\/doi.org\/10.1245\/s10434-020-08361-5.","journal-title":"Ann Surg Oncol"},{"key":"2108_CR29","doi-asserted-by":"publisher","first-page":"705720","DOI":"10.3389\/fonc.2021.705720","volume":"11","author":"J Chen","year":"2021","unstructured":"Chen J, Yin J, Li Y, et al. Systematic lymph node dissection may be abolished in patients with apparent early-stage low-grade mucinous and endometrioid epithelial ovarian cancer. Front Oncol. 2021;11:705720. https:\/\/doi.org\/10.3389\/fonc.2021.705720.","journal-title":"Front Oncol"},{"issue":"3","key":"2108_CR30","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/AOG.0000000000001867","volume":"129","author":"A Gockley","year":"2017","unstructured":"Gockley A, Melamed A, Bregar AJ, et al. Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer. Obstet Gynecol. 2017;129(3):439\u201347. https:\/\/doi.org\/10.1097\/AOG.0000000000001867.","journal-title":"Obstet Gynecol"},{"issue":"5","key":"2108_CR31","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3390\/cancers16050955","volume":"16","author":"R Montero-Mac\u00edas","year":"2024","unstructured":"Montero-Mac\u00edas R, Segura-Sampedro JJ, Rigolet P, et al. The role of systematic lymphadenectomy in low-grade serous ovarian cancer: a systematic review and meta-analysis. Cancers (Basel). 2024;16(5):955. https:\/\/doi.org\/10.3390\/cancers16050955.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2108_CR32","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s11864-024-01205-4","volume":"25","author":"A Gonzalez","year":"2024","unstructured":"Gonzalez A, Nagel CI, Haight PJ. Targeted therapies in low-grade serous ovarian cancers. Curr Treat Options Oncol. 2024;25(7):854\u201368. https:\/\/doi.org\/10.1007\/s11864-024-01205-4.","journal-title":"Curr Treat Options Oncol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-026-02108-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02108-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02108-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T22:54:58Z","timestamp":1780268098000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-026-02108-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2108"],"URL":"https:\/\/doi.org\/10.1186\/s13048-026-02108-8","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Ethical Committee of Qilu Hospital of Shandong University (protocol number KYLL-202011-158-1) and obtained a waiver for informed consent. Before the analysis, the privacy of each patient was maintained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"199"}}